Complete Revascularization Versus Culprit Lesion Only PCI in NSTEMI
Recruiting
N/A
Interventional Study
Non-ST-elevation Myocardial Infarction
Multivessel Coronary Artery Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 3,390 (estimated)
- Sponsor
- Leipzig Heart Science gGmbH · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Prospective, randomized, controlled, multicenter, open-label trial to study whether multivessel percutaneous coronary intervention (PCI) is superior over culprit-lesion only PCI in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery disease.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* NSTEMI as suggested by high-sensitivity troponin algorithms
* Multivessel coronary artery disease
* Identifiable culprit lesion
* Informed consent
Exclusion Criteria:
* Age \<18 years
* Cardiogenic shock
* Sustained ventricular tachycardia (VT) or ventricular fibrillation (V…
Contacts
Hans-Josef Feistritzer, MD, PhD; Assoc. Prof.
+49 341 865252579
COMPLE-NSTEMI@leipzig-heart.de
CONTACT